Aytu Biopharma, Inc (AYTU) — 10-Q Filings
All 10-Q filings from Aytu Biopharma, Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
AYTU Swings to Profit on Warrant Gains, Revenue Dips 16%
— Nov 13, 2025 Risk: medium
AYTU BioPharma, Inc. reported a net income of $1.965 million for the three months ended September 30, 2025, an increase from $1.474 million in the same period o -
Aytu BioPharma Files 10-Q, Reports Q3 2025 Financials
— May 14, 2025 Risk: medium
Aytu BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $6,170,162 in current assets and $5,972,638 in current liabilitie -
Aytu BioPharma Files 10-Q, Reports Q2 Revenue
— Feb 12, 2025 Risk: medium
Aytu BioPharma, Inc. filed its 10-Q for the period ending December 31, 2024. The company reported $6,169,681 in revenue for the period. A significant event note -
Aytu BioPharma Files 10-Q, Details Warrant Exercises
— Nov 13, 2024 Risk: medium
Aytu BioPharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported $6,149,202 in total assets and $5,972,638 in total liabilitie -
AYTU BIOPHARMA, INC. Files 10-Q for Period Ending March 31, 2024
— May 15, 2024 Risk: low
AYTU BIOPHARMA, INC (AYTU) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. AYTU BIOPHARMA, INC. filed a 10-Q report for the period ending March 31 -
AYTU BIOPHARMA, INC. Files 10-Q for Period Ending December 31, 2023
— Feb 14, 2024 Risk: low
AYTU BIOPHARMA, INC (AYTU) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. AYTU BIOPHARMA, INC. filed a 10-Q report for the period ending Dec
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX